Ocugen Reports Encouraging Results and DSMB Assessment, Launches Participant Recruitment for Intermediate Dosage Trial of OCU410, a Genetic Treatment Option, in Early-Stage ArMaDa Research Targeting Geographic Atrophy.

Cidara Therapeutics uses its Cloudbreak technology to develop novel drug-Fc conjugates. The company will showcase four posters at the AACR Annual Meeting.

Adcentrx Therapeutics will showcase early-stage findings of their Nectin-4 antibody-drug conjugate (ADC) initiative at the 2024 AACR Annual Convention.

Carisma Therapeutics reported its Q4 financial results and year-end figures as of December 31, 2023, and provided a corporate update.

The FDA has cleared VOYDEYA™ for use alongside ravulizumab or eculizumab in managing extravascular hemolysis among adult patients with the uncommon disorder PNH.

Vertex Pharmaceuticals Incorporated revealed the progression of inaxaplin (VX-147) to the critical Phase 3 segment of the worldwide Phase 2/3 clinical study focusing on APOL1-related renal conditions.

Asha Therapeutics has revealed its selection of an innovative internal-binding compound, designated ASHA-624, intended as a treatment agent to alter the progression of Amyotrophic Lateral Sclerosis.

The U.S. authorities have endorsed the review of a licensing request for Datopotamab Deruxtecan.

IASO Bio has disclosed official authorization from the China National Medical Products Administration for the clinical trial application of Equecabtagene Autoleucel.

Bristol Myers Squibb Reveals Key Outcomes from KRYSTAL-12 Study on KRAZATI (adagrasib) Demonstrating Main Goal of Halting Disease Progress in Advanced KRASG12C-Altered Non-Small Cell Lung Cancer.

The EU Commission has approved the use of Merck's drug KEYTRUDA® (pembrolizumab) in combination with chemotherapy as a first treatment.

Encouraging initial human trial Phase 1B results for VRON-0200, an innovative checkpoint modifier for Chronic Hepatitis B, were showcased as a late-breaking entry at the APASL 2024 Global Liver Conference.